What is Kezar Life Sciences Inc (KZR) stock price today?

Kezar Life Sciences Inc (KZR) currently trades at $7.31 per share. The stock has a market capitalization of $53.59M and a P/E ratio of —x.

Is KZR stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Kezar Life Sciences Inc has a Smart Value Score of 33/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is -1.90.

Is Kezar Life Sciences Inc financially healthy?

Kezar Life Sciences Inc's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of -1.90 places it in the distress.

KZR

Kezar Life Sciences Inc

NASDAQ: KZR · HEALTHCARE · BIOTECHNOLOGY

$7.31

+0.14% today

Updated 2026-04-30

Market cap

$53.59M

P/E ratio

—

P/S ratio

6.03x

EPS (TTM)

$-7.66

Dividend yield

—

52W range

$4 – $8

Volume

0.1M

Market cap

$53.59M

P/E ratio

—

P/S ratio

6.03x

EPS (TTM)

$-7.66

Dividend yield

—

52W range

$4 – $8

Volume

0.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.5

Quality

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-1.9

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →204 stocks currently score above 75

Price targets

Analyst target

$7.00

-4.24%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy0 Buy3 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.12x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -1.90 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-11.96M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$7.00M	$0.00	$0.00	$0.00
Net income	$-65.32M	$-101.87M	$-83.74M	$-56.03M	$-14.55M
EPS	—	—	—	—	$-7.66
Free cash flow	$-60.42M	$-83.45M	$-74.24M	$-51.78M	$-11.96M
Profit margin	—	-1,455.29%	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
KZR	$53.59M	33	4.3	3.0	5.0	6.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Kezar Life Sciences Inc trades at $7.31. Our Smart Value Score of 33/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -1.90, it sits in the distress.

Frequently asked questions

What is Kezar Life Sciences Inc's stock price?

Kezar Life Sciences Inc (KZR) trades at $7.31.

Is Kezar Life Sciences Inc overvalued?

Smart Value Score 33/100 (Grade F, Strong Sell).

What is the price target of Kezar Life Sciences Inc (KZR)?

The analyst target price is $7.00, representing -4.2% downside from the current price of $7.31.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

-1.90 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.kezarlifesciences.com

Quick metrics

P/S ratio6.03x

ROE-59.90%

Beta0.43

50D MA$6.95

200D MA$5.64

Shares out0.01B

Float0.01B

Short ratio—

Avg volume0.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

KZR vs LLY →KZR vs JNJ →KZR vs ABBV →Stock screener →